



# Metabolic monitoring for patients receiving atypical antipsychotics

Tool intended for use in monitoring and management of antipsychotics after appropriate patient assessment (e.g., indication, comorbid conditions, family history, etc.)



## SGA Risk of Metabolic Disturbances



## Legend

BMI	Body Mass Index
BG	Blood Glucose
SGA	Second Generation Antipsychotic

## References:

American Diabetes Association. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes care*, 27(2), 596-601.

Healthcare Effectiveness Data and Information Set (HEDIS). (2020). *Metabolic Monitoring for Children and Adolescents on Antipsychotics*. National Committee for Quality Assurance.

Zhang, Y., et al. (2017). The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC psychiatry*, 17(1), 373.

Walkup, J. (2009). Practice parameter on the use of psychotropic medication in children and adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry*, 48(9), 961-973.

